It has been shown that the suppression of MAL2 has enhanced the cytotoxicity of tumor-infiltrating CD8+ T cells and suppressed breast tumor growth, which suggests that this gene can be a potential biomarker for breast cancer therapy [38]. The gene discussed is MAL2; the disease is neoplasm.